2:21 PM
Dec 01, 2017
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Innate sees no development path for lirilumab combo therapies

Innate Pharma S.A. (Euronext:IPH) said efficacy data from a Phase I/II trial of lirilumab (BMS-986015, IPH2102) in combination with Opdivo nivolumab to treat head and neck cancers "did not provide clear evidence of benefit to patients or an obvious development path." The partners said they are in discussions to decide on a path forward for the candidate.

The double-blind,...

Read the full 274 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >